Category Archives: Dpp-4 Inhibitor

Maryland Researchers Enrolling Type 2 Patients in Long-Term Drug Study

BALTIMORE-Researchers at the University of Maryland School of Medicine are enrolling patients with type 2 diabetes into an NIH-funded clinical trial to evaluate the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication. The University of Maryland Medical Center and the Baltimore VA Medical Center, … Continue reading Maryland Researchers Enrolling Type 2 Patients in Long-Term Drug Study

Lilly Begins Sales of Jentadueto, a Combo Drug for Type 2s

Eli Lilly and Company has begun US sales of Jentadueto, a drug for type 2 diabetes that combines Tradjenta and metformin. The drug, in tablet form, is taken twice daily and is available in three prescription strengths. Tradjenta (linagliptin) is a DPP-4 inhibitor that regulates insulin levels. The drug was introduced less than a year … Continue reading Lilly Begins Sales of Jentadueto, a Combo Drug for Type 2s

FDA OKs Sale of Combo Drug JANUMET

The FDA has approved US sales of JANUMET® XR, a daily oral treatment for type 2 diabetes that combines sitagliptin and extended-release metformin. The drug is the fourth oral type 2 diabetes treatment introduced by Merck, which also sells JANUVIA, JANUMET, and JUVISYNC. Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that reduces the production of … Continue reading FDA OKs Sale of Combo Drug JANUMET

A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes

Combination therapy, in which doctors prescribe more than one drug to treat type 2 diabetes, is a fairly common practice. However, most newly diagnosed type 2 patients start off with metformin or a sulfonylurea and don’t go on a two-drug therapy until their first drug begins to lose its effectiveness.

But combination therapy could soon become … Continue reading A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes